Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907241 · ClinicalTrials.gov registry record · Phase 3
Clinical Phase III Study TO Monitor THE Safety, Tolerability AND Efficacy OF Subcutaneous Human Immunoglobulin (octanorm) IN Patients With Primary Immunodeficiency Diseases, Including (BUT NOT Limited TO) Those WHO Have Completed THE Scgam-01 Trial
A Phase 3 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
NCT03907241 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 27 participants.
The verdict
NCT03907241, a Phase 3 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
Study Summary
Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial. Summary for SCGAM-03 in Canada: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases, including (but not limited to) those who have completed the SCGAM-01 trial
Interventions
- DRUG Octanorm 16.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-03-01 |
| Est. Completion | 2019-09-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907241
The ClinicalTrials.gov registry entry for NCT03907241 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Octanorm 16.5% is the first listed.
NCT03907241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03907241 about?
NCT03907241 is a clinical study titled "Clinical Phase III Study TO Monitor THE Safety, Tolerability AND Efficacy OF Subcutaneous Human Immunoglobulin (octanorm) IN Patients With Primary Immunodeficiency Diseases, Including (BUT NOT Limited TO) Those WHO Have Completed THE Scgam-01 Trial". Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial. Summary for SCGAM-03 in Canada: Clinical phase III study to monit...
What is the current status of trial NCT03907241?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2016-03-01. Estimated completion is 2019-09-05.
What interventions are being tested in trial NCT03907241?
The interventions under investigation include: Octanorm 16.5% (DRUG).
Who is sponsoring clinical trial NCT03907241?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.